Navigation Links
Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific,Anticalin in Preclinical Studies

FREISING-WEIHENSTEPHAN, Germany, March 29, 2007 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing therapeutic products comprising of Anticalins(R), a novel proprietary class of human binding proteins, announced today it has demonstrated potent anti-tumor activity of PRS-050. The positive results with PRS-050, a VEGF-specific Anticalin(R) with extended serum half life, were achieved in a tumor xenograft model, thereby supporting the development of a superior biotherapeutic for a range of cancer indications.

PRS-050 targets VEGF, a key positive regulator of angiogenesis important in several diseases including cancer and neovascular eye disorders. PRS-050 exhibits a favorable binding and functional in vitro activity profile in direct comparison to all currently approved VEGF antagonists. Strong reduction of VEGF-induced enhanced vascular permeability after systemic administration of PRS-050 was also demonstrated in a second preclinical model. In both in vivo models PRS-050 was at least as efficacious as Avastin(R) (bevacizumab; Genentech / Roche). The data will be presented at CHI's forthcoming Protein Engineering Summit in Boston, USA.

"This example highlights perfectly how Pieris is able to adapt pharmacokinetic properties of Anticalins(R) depending on the intended therapeutic use. It took less than three months after identification of an optimized Anticalin(R) to validate the approach in vivo," comments Dr Andreas Hohlbaum, Director of Science and Preclinical Development of Pieris.

"We have unequivocally demonstrated the drug development potential of Anticalins(R) using well-accepted disease relevant preclinical models," says Evert Kuppers, Chief Executive Officer of Pieris. "With our PRS-050 we have now established a solid fundament for developing the next generation of anti-angiogenesis inhibitors with a favorable product profile."

Notes to Editors

About Pie
'"/>




Page: 1 2 3

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
Post Your Comments:
(Date:10/30/2014)... Mass. , Oct. 30, 2014 Boston ... to participate in the 2014 Credit Suisse Annual Healthcare ... Phoenix , AZ.  Dan Brennan , executive ... presentation about the company beginning at approximately 8:00 a.m. ... A live webcast of the presentation and question ...
(Date:10/30/2014)... , Oct. 30, 2014   ViaDerma, ... devoted to bringing new products to market, has ... called TetraStem. TetraStem is a topical liquid tetracycline-based ... system that can convert oral medication active ingredients ... as a first aid antibiotic to help prevent ...
(Date:10/30/2014)... , Oct. 30, 2014 CVS Health (NYSE: ... new clinical affiliations with three leading regional health systems to ... The collaborating health systems include Baptist Health System in ... which include Commonwealth Health in Pennsylvania , ... Arizona , and Tennova Healthcare in Tennessee ...
Breaking Medicine Technology:Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4
(Date:10/30/2014)... Five months after their expansion, the ... announces new branding and a website to accompany their ... David Mepham’s promotion to name partner earlier this year, ... include Mepham’s name and better reflect their combined litigation ... the decision to implement new branding reflects Hodgkinson Street ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... prostate cancer who also have certain heart problems may increase ... study suggests. , , The therapy in question is called androgen ... levels of male hormones to prevent the growth of cancer ... this hormone therapy was linked to triple the risk of ...
(Date:10/30/2014)... IL (PRWEB) October 30, 2014 Dr. Joseph ... a new website for his practices; OB GYN in ... IL . This website contains important information about each ... as well as downloadable patient forms in English and Spanish. ... and the service pages on the website provide Dr. Furlin’s ...
(Date:10/30/2014)... REV'D Provision Co. announced today that REV’D® ... unique service called, The Feed . The Feed ... athlete. The Feed has taken the nutritional knowledge used ... to pass that information on to the everyday athlete. ... on The Feed!” says REV’D® marketing manager Matt O’Connor. ...
(Date:10/30/2014)... Sound Telecom, a leader in the call center industry, just ... they wonder, “Should I use an answering service?” The graphic ... a series of yes or no questions that ultimately ends ... many considerations and scenarios that come into play when deciding ... This decision infographic serves as a bit of a map ...
Breaking Medicine News(10 mins):Health News:Hodgkinson Street Mepham Rebrands 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2
... TAMPA, Fla., Sept. 1 Amazing medical advancements are made ... been before. As a result, people are living longer lives. While ... population and new medical discoveries has created a huge demand for ... -- from one-year Licensed Practical Nurse (LPN) certifications ...
... September 1, 2009Patients with advanced illnesses more than doubled ... health plan made hospice care more readily accessible, according ... Journal of Palliative Medicine , a peer-reviewed publication ... of Palliative Medicine is the official journal of ...
... a myriad of diseases, including cancer, heart disease and ... for delivering genes to cells both efficiently and safely ... University researchers has introduced the power of nanodiamonds as ... in one approach: enhanced delivery efficiency along with outstanding ...
... , , CHICAGO, Sept. ... "Project Runway," launched a new online video series, called " Living ... national HIV and AIDS education initiative. The Living Positive By ... videos aim to encourage thoughtful conversations about HIV and AIDS, to ...
... , BOSTON, Sept. 1 AMR ... supply chain and its supporting technologies, is proud to announce that ... research for the firm, was named to PharmaVOICE,s list of the ... , , According to PharmaVOICE,s July/August edition, "One ...
... CINCINNATI, Sept. 1 Healthy Advice ... patient-education programs has announced that SIGVARIS, the world,s leading ... the Skin Care Network to broaden their educational coverage. ... an ideal place to increase the awareness of Chronic ...
Cached Medicine News:Health News:Saving Lives Is a Growth Industry 2Health News:Saving Lives Is a Growth Industry 3Health News:Expanded insurance benefits break down barriers to hospice care, according to new study 2Health News:Promise of nanodiamonds for safer gene therapy 2Health News:Promise of nanodiamonds for safer gene therapy 3Health News:Video: 'Project Runway' Designer Launches New Online Video Series to Educate About Living with HIV and AIDS and Help Combat HIV Stigma 2Health News:Video: 'Project Runway' Designer Launches New Online Video Series to Educate About Living with HIV and AIDS and Help Combat HIV Stigma 3Health News:AMR Research Analyst Named One of the Most Inspiring Individuals in Life Sciences by PharmaVOICE 2Health News:AMR Research Analyst Named One of the Most Inspiring Individuals in Life Sciences by PharmaVOICE 3Health News:SIGVARIS USA Extends Educational Efforts in Healthy Advice's Skin Care Network 2Health News:SIGVARIS USA Extends Educational Efforts in Healthy Advice's Skin Care Network 3
Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
... ,Offers an average 5:1 increase in usage ... use of a standard cannula. , ,The ... offers ambulatory oxygen patients a superior alternative to ... 2-year warranty. , ...
Redesigning the World's Oxygen Therapy One Device at a Time. , ,Everything you like about our OXYMATIC 400 Series conservers, only better!...
Includes conservation device, matched regulator, standard supply tubing, cannula, carrying case, batteries, and instruction booklet....
Medicine Products: